# Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)

> **NCT04721795** · PHASE2,PHASE3 · COMPLETED · sponsor: **Obafemi Awolowo University Teaching Hospital** · enrollment: 150 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis

## Interventions

- **DRUG:** Atorvastatin with standard anti tuberculosis drugs
- **DRUG:** Standard anti tuberculosis drugs only

## Key facts

- **NCT ID:** NCT04721795
- **Lead sponsor:** Obafemi Awolowo University Teaching Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-19
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721795, "Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04721795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*